Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma or Hodgkin’s Disease) of the lymphatic system and is one of two common types of cancers of the lymphatic system. The inclusion of Reed Sternberg cells, a type of white blood cell called a B lymphocyte, helps clinicians to delineate HL from other types of lymphoma. The primary site for HL in most patients will be the lymph nodes in the neck, but as a cancer that affects the lymphatic system, it has the potential to start anywhere in the body at the same time and to spread to different organs.
This report provides the current incident population for Hodgkin’s Lymphoma across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Australia, Argentina, Canada, India, Mexico, Russian Federation, Saudi Arabia, South Africa and Turkey) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Hodgkin’s Lymphoma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
The most common symptom of HL is painless swelling of the lymph nodes, however there are other signs that can indicate HL, including:
• Night sweats
• Itchy skin
• Unexplained fever
• Fatigue
• Unintended weight loss
• Persistent cough
• Pain in the lymph nodes after consuming alcohol
• Enlarged spleen
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Hodgkin’s Lymphoma market to target the development of future products, pricing strategies and launch plans.
• Gain further insights into the incidence of the subdivided types of Hodgkin’s Lymphoma and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Hodgkin’s Lymphoma incident population.
• Identify sub-populations within Hodgkin’s Lymphoma which require treatment.
• Gain an understanding of the specific markets that have the largest number of Hodgkin’s Lymphoma patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line incidence for Hodgkin’s Lymphoma
• Stages and systemic symptoms at diagnosis of Hodgkin’s Lymphoma
o Staging of Hodgkin’s Lymphoma
• Co-morbid conditions in Hodgkin’s Lymphoma patients
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Figures
• Diagrammatic representation of the Lymphatic System
List of Tables
• Cotswold Modification of the Ann Arbor Staging System
• Incidence of Hodgkin’s Lymphoma, total (000s)
• Incidence of Hodgkin’s Lymphoma, males (000s)
• Incidence of Hodgkin’s Lymphoma, females (000s)
• Hodgkin’s Lymphoma by stage, total (000s)
• Patients with systemic symptoms at diagnosis of Hodgkin’s Lymphoma, total (000s)
• HL patients by International Prognosis Score, total (000s)
• Cachexia in patients with Hodgkin’s Lymphoma, total (000s)
• Haemolytic Anaemia in patients with Hodgkin’s Lymphoma, total (000s)
• EBV-Associated Hodgkin’s Lymphoma, total (000s)
• Abbreviations and Acronyms used in the report
• USA incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• USA incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• France incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• France incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Germany incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Germany incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Italy incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Italy incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Spain incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Spain incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• UK incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• UK incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Brazil incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Brazil incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Japan incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Japan incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Australia incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Australia incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Argentina incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Argentina incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Canada incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Canada incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• India incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• India incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Mexico incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Mexico incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Russian Federation incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Russian Federation incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Saudi Arabia incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Saudi Arabia incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• South Africa incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• South Africa incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
• Turkey incidence of Hodgkin’s Lymphoma by 5-yr age cohort, males (000s)
• Turkey incidence of Hodgkin’s Lymphoma by 5-yr age cohort, females (000s)
